Fig. 4From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patientsBiomarker levels in serum during treatment. PRO-C3, C1M, C3M, C4M and VICM levels in serum at baseline (n = 52) and 3 weeks after ipilimumab treatment (n = 52). The black horizontal lines represent the median value of the patients. Serum levels were compared using Wilcoxon matched-pairs rank test. Asterisks indicate the following: **, p < 0.01 and ****, p < 0.0001Back to article page